Treatment Considerations in Refractory CRC

EP. 1: Introduction: Expanded RAS Testing in Colorectal Cancer

February 26th 2014

EP. 2: Optimizing Treatment With EGFR Inhibitors in CRC

February 26th 2014

EP. 3: Clinical Development of Cetuximab in mCRC

February 26th 2014

EP. 4: Upfront Bevacizumab and Cetuximab Compared in mCRC

February 26th 2014

EP. 5: Treatment of Unresectable RAS Wild-type Metastatic CRC

February 26th 2014

EP. 6: First- and Later-line Use of Panitumumab in mCRC

February 26th 2014

EP. 7: Considerations When Selecting an EGFR Inhibitor in mCRC

February 26th 2014

EP. 8: Role of the Multikinase Inhibitor Regorafenib in mCRC

February 26th 2014

EP. 9: Role of the VEGF Inhibitor Aflibercept in mCRC

February 26th 2014

EP. 10: New Therapies in Development for mCRC

February 26th 2014

EP. 11: Tumor Profiling in Patients With mCRC

February 26th 2014

EP. 12: Current Trends in the Treatment of CRC

February 26th 2014

EP. 13: First- and Second-Line Treatment of mCRC in Specific Populations

February 26th 2014

EP. 14: Third-Line Treatment Options for mCRC

February 26th 2014

EP. 15: Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC

February 26th 2014

EP. 16: Final Thoughts on the Treatment of mCRC

February 26th 2014